[1] Johnston, M. C., Crilly, M., Black, C., Prescott, G. J., & Mercer, S. W. (2019). Defining and measuring multimorbidity: A systematic review of systematic reviews. European Journal of Public Health, 29(1), 182–189. https://doi.org/10.1093/eurpub/cky098

[2] Chowdhury, S. R., Chandra Das, D., Sunna, T. C., Beyene, J., & Hossain, A. (2023). Global and regional prevalence of multimorbidity in the adult population in community settings: A systematic review and meta-analysis. EClinicalMedicine, 57, 101860. https://doi.org/10.1016/j.eclinm.2023.101860

[3] Asogwa, O. A., Boateng, D., Marzà-Florensa, A., Peters, S., Levitt, N., van Olmen, J., & Klipstein-Grobusch, K. (2022). Multimorbidity of non-communicable diseases in low-income and middle-income countries: A systematic review and meta-analysis. BMJ Open, 12(1), e049133. https://doi.org/10.1136/bmjopen-2021-049133

[4] Tran, P. B., Kazibwe, J., Nikolaidis, G. F., Linnosmaa, I., Rijken, M., & van Olmen, J. (2022). Costs of multimorbidity: A systematic review and meta-analyses. BMC Medicine, 20(1), 234. https://doi.org/10.1186/s12916-022-02427-9

[5] Al-Mansouri, A., Hamad, A. I., Al-Ali, F. S., Ibrahim, M. I. M., Kheir, N., Al-Ziftawi, N. H., Ibrahim, R. A., AlBakri, M., & Awaisu, A. (2023). Pill-burden and its association with treatment burden among patients with advanced stages of chronic kidney disease. Saudi Pharmaceutical Journal, 31(5), 678– 686. https://doi.org/10.1016/j.jsps.2023.03.008

[6] Kernick, D., Chew-Graham, C. A., & O’Flynn, N. (2017). Clinical assessment and management of multimorbidity: NICE guideline. The British Journal of General Practice, 67(658), 235–236. https://doi.org/10.3399/bjgp17X690857

[7] van Merode, T., van de Ven, K., & van den Akker, M. (2018). Patients with multimorbidity and their treatment burden in different daily life domains: A qualitative study in primary care in the Netherlands and Belgium. Journal of Comorbidity, 8(1), 9–15. https://doi.org/10.15256/joc.2018.8.119

[8] Rosbach, M., & Andersen, J. S. (2017). Patientexperienced burden of treatment in patients with multimorbidity: A systematic review of qualitative data. PLoS One, 12(6), e0179916. https://doi.org/10.1371/journal.pone.0179916

[9] Charani, E., Cunnington, A. J., Yousif, A. H. A., Seed Ahmed, M., Ahmed, A. E. M., Babiker, S., Badri, S., Buytaert, W., Crawford, M. A., Elbashir, M. I., Elhag, K., Elsiddig, K. E., Hakim, N., Johnson, M. R., Miras, A. D., Swar, M. O., Templeton, M. R., & Taylor-Robinson, S. D. (2019). In transition: Current health challenges and priorities in Sudan. BMJ Global Health, 4(4), e001723. https://doi.org/10.1136/bmjgh-2019-001723

[10] Alorini, M., Omar, S., Abubaker, M., & Adam, I. (2023). Multimorbidity in Sudanese women newly diagnosed with breast cancer: A retrospective cross-sectional study. F1000 Research, 12, 89. https://doi.org/10.12688/f1000research.127325.1

[11] Lucero-Prisno, D. E., III, Elhadi, Y. A. M., Modber, M. A. A., Musa, M. B., Mohammed, S. E. E., Hassan, K. F., Dafallah, A., Lin, X., Ahmadi, A., Adeyemi, S., Ekpenyong, A., & Adebisi, Y. A. (2020). Drug shortage crisis in Sudan in times of COVID-19. Public Health in Practice (Oxford, England), 1, 100060. https://doi.org/10.1016/j.puhip.2020.100060

[12] Ebrahim, E. M. A., Ghebrehiwot, L., Abdalgfar, T., & Juni, M. H. (2017). Health care system in Sudan: Review and analysis of strength, weakness, opportunity, and threats (SWOT analysis). Sudan Journal of Medical Sciences, 12(3), 133–150. https://doi.org/10.18502/sjms.v12i3.924

[13] Duncan, P., Murphy, M., Man, M. S., Chaplin, K., Gaunt, D., & Salisbury, C. (2018). Development and validation of the Multimorbidity Treatment Burden Questionnaire (MTBQ). BMJ Open, 8(4), e019413. https://doi.org/10.1136/bmjopen-2017-019413

[14] Ismail, S., Stanley, A., & Jeemon, P. (2022). Prevalence of multimorbidity and associated treatment burden in primary care settings in Kerala: A cross-sectional study in Malappuram District, Kerala, India. Wellcome Open Research, 7, 67. https://doi.org/10.12688/wellcomeopenres.17674.2

[15] Guénette, L., Turcotte, V., Bélanger, L., Blais, L., Sirois, C., Lunghi, C., & Duncan, P. (2023). Multimorbidity Treatment Burden Questionnaire (MTBQ): Translation, cultural adaptation, and validation in French-Canadian. Canadian Journal on Aging, 42(1), 126–134. https://doi.org/10.1017/S0714980822000058

[16] Morris, J. E., Roderick, P. J., Harris, S., Yao, G., Crowe, S., Phillips, D., Duncan, P., & Fraser, S. D. (2021). Treatment burden for patients with multimorbidity: Cross-sectional study with exploration of a single-item measure. The British Journal of General Practice, 71(706), e381–e390. https://doi.org/10.3399/BJGP.2020.0883

[17] Eyowas, F. A., Schneider, M., Alemu, S., & Getahun, F. A. (2023). Experience of living with multimorbidity and health workers perspectives on the organization of health services for people living with multiple chronic conditions in Bahir Dar, northwest Ethiopia: A qualitative study. BMC Health Services Research, 23(1), 232. https://doi.org/10.1186/s12913-023-09250- 9

[18] Roomaney, R. A., van Wyk, B., & Pillay-van Wyk, V. (2022). A systematic method for comparing multimorbidity in national surveys. BMC Research Notes, 15(1), 280. https://doi.org/10.1186/s13104-022- 06164-3

[19] Pedersen, M. H., Duncan, P., Lasgaard, M., Friis, K., Salisbury, C., & Breinholt Larsen, F. (2022). Danish validation of the Multimorbidity Treatment Burden Questionnaire (MTBQ) and findings from a population health survey: A mixed-methods study. BMJ Open, 12(1), e055276. https://doi.org/10.1136/bmjopen-2021-055276

[20] Dou, L., Huang, J., Duncan, P., & Guo, L. (2020). Translation, cultural adaptation and validation of the Chinese Multimorbidity Treatment Burden Questionnaire(C-MTBQ): A study of older hospital patients. Health and Quality of Life Outcomes, 18(1), 194. https://doi.org/10.1186/s12955-020-01395-z

[21] Schulze, J., Breckner, A., Duncan, P., Scherer, M., Pohontsch, N. J., & Lühmann, D. (2022). Adaptation and validation of a German version of the Multimorbidity Treatment Burden Questionnaire. Health and Quality of Life Outcomes, 20(1), 90. https://doi.org/10.1186/s12955-022-01993-z

[22] Basto-Abreu, A., Barrientos-Gutierrez, T., Wade, A. N., Oliveira de Melo, D., Seme ao de Souza, A. S., Nunes, B. P., Perianayagam, A., Tian, M., Yan, L. L., Ghosh, A., & Miranda, J. J. (2022). Multimorbidity matters in low and middle-income countries. Journal of Multimorbidity and Comorbidity, 12, 26335565221106074. https://doi.org/10.1177/26335565221106074

[23] Elhadi, Y. A. M., Ahmed, A., Ghazy, R. M., Salih, E. B., Abdelhamed, O. S., Shaaban, R., Mohamed, H. M. H., Mohamed, A. E., El Dabbah, N. A., & Zaghloul, A. A. Z. (2022). Healthcare utilization with drug acquisition and expenses at the National Health Insurance Fund in Sudan. Healthcare (Basel), 10(4), 630. https://doi.org/10.3390/healthcare10040630